|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Olaussen KA, Dunant A, Fouret P, Brambilla
E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH,
et al: DNA repair by ERCC1 in non-small-cell lung cancer and
cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Costa PM, Ferreira PM, Bolzani Vda S,
Furlan M, de Freitas Formenton Macedo Dos Santos VA, Corsino J, de
Moraes MO, Costa-Lotufo LV, Montenegro RC and Pessoa C:
Antiproliferative activity of pristimerin isolated from Maytenus
ilicifolia (Celastraceae) in human HL-60 cells. Toxicol In Vitro.
22:854–863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tu Y, Tan F, Zhou J and Pan J: Pristimerin
targeting NF-κB pathway inhibits proliferation, migration, and
invasion in esophageal squamous cell carcinoma cells. Cell Biochem
Funct. 36:228–240. 2018. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yousef BA, Hassan HM, Zhang LY and Jiang
ZZ: Pristimerin exhibits in vitro and in vivo anticancer activities
through inhibition of nuclear factor-small ka, CyrillicB signaling
pathway in colorectal cancer cells. Phytomedicine. 40:140–147.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cevatemre B, Erkisa M, Aztopal N, Karakas
D, Alper P, Tsimplouli C, Sereti E, Dimas K, Armutak EII, Gurevin
EG, et al: A promising natural product, pristimerin, results in
cytotoxicity against breast cancer stem cells in vitro and
xenografts in vivo through apoptosis and an incomplete autopaghy in
breast cancer. Pharmacol Res. 129:500–514. 2018. View Article : Google Scholar
|
|
8
|
Liu YB, Gao X, Deeb D, Arbab AS and Gautam
SC: Pristimerin induces apoptosis in prostate cancer cells by
down-regulating Bcl-2 through ROS-dependent ubiquitin-proteasomal
degradation pathway. J Carcinog Mutagen. (Suppl 6): 0052013.
|
|
9
|
Zhang B, Zhang J and Pan J: Pristimerin
effectively inhibits the malignant phenotypes of uveal melanoma
cells by targeting NFkappaB pathway. Int J Oncol. 51:887–898. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Deeb D, Gao X, Liu Y, Pindolia K and
Gautam SC: Inhibition of hTERT/telomerase contributes to the
antitumor activity of pristimerin in pancreatic ductal
adenocarcinoma cells. Oncol Rep. 34:518–524. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gao X, Liu Y, Deeb D, Arbab AS and Gautam
SC: Anticancer activity of pristimerin in ovarian carcinoma cells
is mediated through the inhibition of prosurvival
Akt/NF-kappaB/mTOR signaling. J Exp Ther Oncol. 10:275–283.
2014.
|
|
12
|
Yan YY, Bai JP, Xie Y, Yu JZ and Ma CG:
The triterpenoid pristimerin induces U87 glioma cell apoptosis
through reactive oxygen species-mediated mitochondrial dysfunction.
Oncol Lett. 5:242–248. 2013. View Article : Google Scholar
|
|
13
|
Chang FR, Hayashi K, Chen IH, Liaw CC,
Bastow KF, Nakanishi Y, Nozaki H, Cragg GM, Wu YC and Lee KH:
Antitumor agents. 228. five new agarofurans, Reissantins A-E, and
cytotoxic principles from Reissantia buchananii. J Nat Prod.
66:1416–1420. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Park JH and Kim JK: Pristimerin, a
naturally occurring triterpenoid, attenuates tumorigenesis in
experimental colitis-associated colon cancer. Phytomedicine.
42:164–171. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yousef BA, Guerram M, Hassan HM, Hamdi AM,
Zhang LY and Jiang ZZ: Pristimerin demonstrates anticancer
potential in colorectal cancer cells by inducing G1 phase arrest
and apoptosis and suppressing various pro-survival signaling
proteins. Oncol Rep. 35:1091–1100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR
and Wu YC: Pristimerin induces caspase-dependent apoptosis in
MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer
Ther. 4:1277–1285. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Zhou Y, Zhou H, Jia G, Liu J, Han
B, Cheng Z, Jiang H, Pan S and Sun B: Pristimerin causes G1 arrest,
induces apoptosis, and enhances the chemosensitivity to gemcitabine
in pancreatic cancer cells. PLoS One. 7:e438262012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie G, Yu X, Liang H, Chen J, Tang X, Wu S
and Liao C: Pristimerin overcomes adriamycin resistance in breast
cancer cells through suppressing Akt signaling. Oncol Lett.
11:3111–3116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
20
|
Zhang K, Xu H, Jia X, Chen Y, Ma M, Sun L
and Chen H: Ultrasound-triggered nitric oxide release platform
based on energy transformation for targeted inhibition of
pancreatic tumor. ACS Nano. 10:10816–10828. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang K, Li P, He Y, Bo X, Li X, Li D,
Chen H and Xu H: Synergistic retention strategy of RGD active
targeting and radiofrequency-enhanced permeability for intensified
RF & chemotherapy synergistic tumor treatment. Biomaterials.
99:34–46. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang K, Li P, Chen H, Bo X, Li X and Xu
H: Continuous cavitation designed for enhancing radiofrequency
ablation via a special radiofrequency solidoid vaporization
process. ACS Nano. 10:2549–2558. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jung D, Khurana A, Roy D, Kalogera E,
Bakkum-Gamez J, Chien J and Shridhar V: Quinacrine upregulates
p21/p27 independent of p53 through autophagy-mediated
downregulation of p62-Skp2 axis in ovarian cancer. Sci Rep.
8:24872018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han Z, Zhou X, Li S, Qin Y, Chen Y and Liu
H: Inhibition of miR-23a increases the sensitivity of lung cancer
stem cells to erlotinib through PTEN/PI3K/Akt pathway. Oncol Rep.
38:3064–3070. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li ZW, Zhao L, Han QC and Zhu X: CXCL13
inhibits microRNA-23a through PI3K/AKT signaling pathway in adipose
tissue derived-mesenchymal stem cells. Biomed Pharmacother.
83:876–880. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu X, Xue X, Wang L, Wang W, Han J, Sun X,
Zhang H, Liu Y, Che X, Yang J and Wu C: Suppressing autophagy
enhances disulfiram/copper-induced apoptosis in non-small cell lung
cancer. Eur J Pharmacol. 827:1–12. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Han C, Xing G, Zhang M, Zhong M, Han Z, He
C and Liu X: Wogonoside inhibits cell growth and induces
mitochondrial-mediated autophagy-related apoptosis in human colon
cancer cells through the PI3K/AKT/mTOR/p70S6K signaling pathway.
Oncol Lett. 15:4463–4470. 2018.PubMed/NCBI
|
|
28
|
Sun CY, Zhu Y, Li XF, Wang XQ, Tang LP, Su
ZQ, Li CY, Zheng GJ and Feng B: Scutellarin increases
cisplatin-induced apoptosis and autophagy to overcome cisplatin
resistance in non-small cell lung cancer via ERK/p53 and c-met/AKT
signaling pathways. Front Pharmacol. 9:922018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Czarnomysy R, Surazynski A, Muszynska A,
Gornowicz A, Bielawska A and Bielawski K: A novel series of
pyrazole-platinum(II) complexes as potential anti-cancer agents
that induce cell cycle arrest and apoptosis in breast cancer cells.
J Enzyme Inhib Med Chem. 33:1006–1023. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ling Z, Guan H, You Z, Wang C, Hu L, Zhang
L, Wang Y, Chen S, Xu B and Chen M: Aloperine executes antitumor
effects through the induction of apoptosis and cell cycle arrest in
prostate cancer in vitro and in vivo. Onco Targets Ther.
11:2735–2743. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ahmad M, Hahn IF and Chatterjee S: GRP78
up-regulation leads to hypersensitization to cisplatin in A549 lung
cancer cells. Anticancer Res. 34:3493–3500. 2014.PubMed/NCBI
|
|
32
|
Sivalingam KS, Paramasivan P, Weng CF and
Viswanadha VP: Neferine potentiates the antitumor effect of
cisplatin in human lung adenocarcinoma cells via a
mitochondria-mediated apoptosis pathway. J Cell Biochem.
118:2865–2876. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang LS, Chen SJ, Zhang JF, Liu MN, Zheng
JH and Yao XD: Anti-proliferative potential of Glucosamine in renal
cancer cells via inducing cell cycle arrest at G0/G1 phase. BMC
Urol. 17:382017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen SH, Gong X, Zhang Y, Van Horn RD, Yin
T, Huber L, Burke TF, Manro J, Iversen PW, Wu W, et al: RAF
inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6
inhibition by abemaciclib via superior inhibition of phospho-RB and
suppression of cyclin D1. Oncogene. 37:821–832. 2018. View Article : Google Scholar
|
|
35
|
Stivala LA, Cazzalini O and Prosperi E:
The cyclin-dependent kinase inhibitor p21CDKN1A as a target of
anti-cancer drugs. Curr Cancer Drug Targets. 12:85–96. 2012.
View Article : Google Scholar
|
|
36
|
Starostina NG and Kipreos ET: Multiple
degradation pathways regulate versatile CIP/KIP CDK inhibitors.
Trends Cell Biol. 22:33–41. 2012. View Article : Google Scholar :
|
|
37
|
Kelly PN and Strasser A: The role of Bcl-2
and its pro-survival relatives in tumourigenesis and cancer
therapy. Cell Death Differ. 18:1414–1424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang H, Landis-Piwowar KR, Lu D, Yuan P,
Li L, Reddy GP, Yuan X and Dou QP: Pristimerin induces apoptosis by
targeting the proteasome in prostate cancer cells. J Cell Biochem.
103:234–244. 2008. View Article : Google Scholar
|
|
39
|
Liu D, You P, Luo Y, Yang M and Liu Y:
Galangin Induces Apoptosis in MCF-7 human breast cancer cells
through mitochondrial pathway and phosphatidylinositol 3-Kinase/Akt
Inhibition. Pharmacology. 102:58–66. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lin W, Xie J, Xu N, Huang L, Xu A, Li H,
Li C, Gao Y, Watanabe M, Liu C and Huang P: Glaucocalyxin A induces
G2/M cell cycle arrest and apoptosis through the PI3K/Akt pathway
in human bladder cancer cells. Int J Biol Sci. 14:418–426. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Deeb D, Gao X, Liu YB, Pindolia K and
Gautam SC: Pristimerin, a quinonemethide triterpenoid, induces
apoptosis in pancreatic cancer cells through the inhibition of
pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic
Bcl-2. Int J Oncol. 44:1707–1715. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bi T, Zhu A, Yang X, Qiao H, Tang J, Liu Y
and Lv R: Metformin synergistically enhances antitumor activity of
cisplatin in gallbladder cancer via the PI3K/AKT/ERK pathway.
Cytotechnology. 70:439–448. 2018. View Article : Google Scholar :
|
|
43
|
Liao XZ, Tao LT, Liu JH, Gu YY, Xie J,
Chen Y, Lin MG, Liu TL, Wang DM, Guo HY and Mo SL: Matrine combined
with cisplatin synergistically inhibited urothelial bladder cancer
cells via down-regulating VEGF/PI3K/Akt signaling pathway. Cancer
Cell Int. 17:1242017. View Article : Google Scholar
|
|
44
|
Zhang R, Li G, Zhang Q, Tang Q, Huang J,
Hu C, Liu Y, Wang Q, Liu W, Gao N and Zhou S: Hirsutine induces
mPTP-dependent apoptosis through ROCK1/PTEN/PI3K/GSK3β pathway in
human lung cancer cells. Cell Death Dis. 9:5982018. View Article : Google Scholar
|
|
45
|
Xue M, Ji X, Xue C, Liang H, Ge Y, He X
and Zhang L, Bian K and Zhang L: Caspase-dependent and
caspase-independent induction of apoptosis in breast cancer by
fucoidan via the PI3K/AKT/GSK3β pathway in vivo and in vitro.
Biomed Pharmacother. 94:898–908. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang Y, Zhao M, Liu J, Sun Z, Ni J and Liu
H: miRNA-125b regulates apoptosis of human non-small cell lung
cancer via the PI3K/Akt/GSK3β signaling pathway. Oncol Rep.
38:1715–1723. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li Z, Lin C, Zhao L, Zhou L, Pan X, Quan
J, Peng X, Li W, Li H, Xu J, et al: Oncogene miR-187-5p is
associated with cellular proliferation, migration, invasion,
apoptosis and an increased risk of recurrence in bladder cancer.
Biomed Pharmacother. 105:461–469. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hu X, Wang Y, Liang H, Fan Q, Zhu R, Cui
J, Zhang W, Zen K, Zhang CY, Hou D, et al: miR-23a/b promote tumor
growth and suppress apoptosis by targeting PDCD4 in gastric cancer.
Cell Death Dis. 8:e30592017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Farooqi AA, Qureshi MZ, Coskunpinar E,
Naqvi SK, Yaylim I and Ismail M: MiR-421, miR-155 and miR-650:
Emerging trends of regulation of cancer and apoptosis. Asian Pac J
Cancer Prev. 15:1909–1912. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ryter SW, Mizumura K and Choi AM: The
impact of autophagy on cell death modalities. Int J Cell Biol.
2014:5026762014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Keta O, Bulat T, Golic I, Incerti S, Korac
A, Petrovic I and Ristic-Fira A: The impact of autophagy on cell
death modalities in CRL-5876 lung adenocarcinoma cells after their
exposure to gamma-rays and/or erlotinib. Cell Biol Toxicol.
32:83–101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cheng X, Feng H, Wu H, Jin Z, Shen X,
Kuang J, Huo Z, Chen X, Gao H, Ye F, et al: Targeting autophagy
enhances apatinib-induced apoptosis via endoplasmic reticulum
stress for human colorectal cancer. Cancer Lett. 431:105–114. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bai XY, Liu YG, Song W, Li YY, Hou DS, Luo
HM and Liu P: Anticancer activity of tetrandrine by inducing
pro-death apoptosis and autophagy in human gastric cancer cells. J
Pharm Pharmacol. 70:1048–1058. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yu X, Lin H, Wang Y, Lv W, Zhang S, Qian
Y, Deng X, Feng N, Yu H and Qian B: d-limonene exhibits antitumor
activity by inducing autophagy and apoptosis in lung cancer. Onco
Targets Ther. 11:1833–1847. 2018. View Article : Google Scholar : PubMed/NCBI
|
